SOUTH SAN FRANCISCO, Calif., May 31, 2026
Genentech, a member of the Roche Group, announced that new clinical data from its obesity portfolio will be presented at the American Diabetes Association (ADA) 2026 Scientific Sessions, highlighting the progress of its investigational weight-management therapies enicepatide (CT-388) and petrelintide. The company said the latest findings reinforce the potential of both candidates to address major unmet needs in obesity treatment, including long-term adherence, efficacy, and tolerability. The data support Genentech’s broader strategy of building a differentiated obesity franchise that can offer individualized treatment options for people living with overweight or obesity.
Enicepatide Shows Promise as a Potential Weight-Loss Backbone Therapy
Late-breaking results from the Phase II CT388-103 study will showcase the clinical weight-loss outcomes achieved with enicepatide, an investigational once-weekly dual GLP-1/GIP receptor agonist. The therapy is being developed for individuals living with obesity and obesity-related conditions, including type 2 diabetes. According to Genentech, enicepatide’s unique signaling profile may provide prolonged pharmacological activity while minimizing receptor desensitization. The company believes the candidate has the potential to become both a standalone treatment and a foundational therapy for future combination regimens within its cardiometabolic portfolio. Additional Phase II studies are currently evaluating its safety, efficacy, and tolerability in patients with obesity and type 2 diabetes.
Petrelintide Delivers Encouraging Efficacy and Tolerability Results
Genentech will also present late-breaking data from the Phase II ZUPREME-1 trial evaluating petrelintide, a long-acting human amylin analog designed for once-weekly administration. The investigational therapy demonstrated encouraging efficacy and safety findings in people living with overweight or obesity, while also showing a favorable tolerability profile that could improve the treatment experience for patients. Petrelintide works by activating amylin receptors, helping restore sensitivity to the satiety hormone leptin and promoting earlier feelings of fullness. Additional research being presented at ADA explores petrelintide’s effects on eating behavior, physical activity, and gastric emptying, further supporting its potential role as a differentiated obesity treatment. The ongoing ZUPREME-2 trial is evaluating petrelintide in patients with obesity or overweight who also have type 2 diabetes..
Advertisement
Combination Development and Phase III Advancement Planned
Building on the encouraging Phase II results, Genentech plans to advance both enicepatide and petrelintide into Phase III development while initiating a new Phase II multi-arm study evaluating fixed-dose combinations of the two therapies in mid-2026. Company leadership stated that the combination approach could provide a differentiated treatment option by leveraging complementary mechanisms of action. According to Genentech Chief Medical Officer Dr. Levi Garraway, the emerging clinical data demonstrate both strong efficacy and distinct tolerability profiles, supporting the goal of delivering more personalized obesity treatments. With obesity affecting billions of people globally and contributing to more than 200 associated health conditions, Genentech believes its expanding pipeline has the potential to play a significant role in addressing one of the world’s largest healthcare challenges.
Source: Genentech press release
